FRANKFURT May 28 Bayer AG said it
has submitted anti-clotting drug Xarelto for marketing
authorisation in Japan for the treatment of deep vein thrombosis
and pulmonary embolism, the German pharmaceuticals company said
The drug has also been submitted for the prevention of
recurrent venous thromboembolism, Bayer said.
Xarelto, one of Bayer's top five new medicines, has been
approved for the treatment of deep vein thrombosis and pulmonary
embolism and PE as well as for the prevention of recurrent DVT
and PE in more than 100 countries worldwide, including Europe
and the United States.
(Reporting by Victoria Bryan; Editing by Christoph Steitz)